Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank75
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Percentile
P75
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
2025-14.45%
2024-25.17%
2023-115.33%
2022-56.66%
2021-165.74%
202061.36%
2019-125.87%
2018-19.90%
20170.00%